Novo Nordisk Pharmatech makes first sales agreement in Mexico

Helm de México is a new ally for the company.

by andreas lønstrup, translated by catherine brett

Published: 24.09.21 at 07:51

Novo Nordisk Pharmatech has entered into an agreement with Helm de México, which will be responsible for the distribution of Novo's Quats (synthetic molecules) in Mexico.

"We are very excited to announce the new distribution agreement between Helm de México and Novo Nordisk Pharmatech. We believe it is a mutually beneficial agreement. On the one hand, Novo Nordisk Pharmatech will gain access to Helm's extensive network of customers in the pharmaceutical/cosmetics industry along with the distribution infrastructure HELM has built in the 55 years we have been present in the Mexican market," Boy Ehlers, Managing Director of Helm de México, says in a Novo Nordisk Pharmatech press release, adding:

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.